Abstract Number: 0831 • ACR Convergence 2023
Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study
Background/Purpose: The STOP-JIA study was designed to compare the effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus Treatment Plans (CTPs) for untreated…Abstract Number: 1439 • ACR Convergence 2023
Better Drug Retention on anti-IL17A Compared to Anti-TNF Therapy Despite Its Inferior Effect on Composite Joint Indexes and Quality of Life in Patients with PsA–analysis from the Czech Biologics Registry ATTRA
Background/Purpose: To compare drug survival, effectiveness and safety of anti-IL17A with anti-TNF drugs as first line biologic therapy in patients (pts) with PsA using real…Abstract Number: 2556 • ACR Convergence 2023
End-of-Life in Systemic Lupus Erythematosus Beset by Increased Flares and Higher Treatment Burden: Data from a Prospective Large Multinational Cohort
Background/Purpose: SLE patients suffer high symptom burden at the end-of-life. However, the course of disease and treatment burden in the last year of life have…Abstract Number: 0980 • ACR Convergence 2023
Temporal Trends in Incidence Rates of Seropositive and Seronegative Rheumatoid Arthritis: A Danish Nationwide Population-based Study
Background/Purpose: With growing availability of autoantibody testing and autoantibodies gaining more weight in the 2010 ACR/EULAR classification criteria of rheumatoid arthritis (RA), an increasing incidence…Abstract Number: 1629 • ACR Convergence 2023
Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative
Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting…Abstract Number: 0987 • ACR Convergence 2023
Risk Factors and Predictors of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
Background/Purpose: Genetic, demographic, clinical, and immunological factors have been related with the response to treatment in inflammatory rheumatic diseases, such as rheumatoid arthritis (RA) and…Abstract Number: 1632 • ACR Convergence 2023
Incident Malignancies in Patients with Rheumatoid Arthritis in Daily Rheumatological Care
Background/Purpose: In 2021, the European and US-American regulatory agencies EMA and FDA issued warnings about malignancy risk associated with the Janus kinase inhibitor (JAKi) tofacitinib…Abstract Number: 0988 • ACR Convergence 2023
Elderly Patients’ Discontinuation of Biologic DMARDs in Patients with Rheumatic Diseases: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
Background/Purpose: The approach to elderly patients (≥60 years) with rheumatic diseases offers certain difficulties and uncertainties. Older adults are a particularly vulnerable group who often…Abstract Number: 1692 • ACR Convergence 2023
Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)
Background/Purpose: JAK-inhibitors (JAKi) are increasingly being prescribed to treat various inflammatory conditions, including psoriatic arthritis (PsA). While the understanding of JAKi efficacy and safety in…Abstract Number: 0139 • ACR Convergence 2023
Systemic Vasculitides in Portugal and Brazil: Preliminary Results from the Reuma.pt/vasculitis Registry
Background/Purpose: The epidemiology of vasculitis varies widely across different geographic areas of the world which may be due to different ethnic and environmental factors. Brazil…Abstract Number: 1024 • ACR Convergence 2023
Relationship Between Race and Ethnicity, Time to Diagnosis, and Disease Activity for Children with Juvenile Idiopathic Arthritis in the CARRA Registry
Background/Purpose: Compared to non-Hispanic White children, Black children diagnosed with juvenile idiopathic arthritis (JIA) have more severe disease at diagnosis and worse outcomes, such as…Abstract Number: 1850 • ACR Convergence 2023
Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data
Background/Purpose: According to recent ACR and EULAR rheumatoid arthritis (RA) guidelines, glucocorticoids (GCs) should only be used for brief periods or not at all. Our…Abstract Number: 0355 • ACR Convergence 2023
Long Term Safety of Drugs in Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Evidence on treatment safety in systemic juvenile idiopathic arthritis (sJIA) is limited. Our objective was to evaluate the safety profile of drugs in the…Abstract Number: 1085 • ACR Convergence 2023
Utilizing a Maintenance of Certification (MOC) Part 4 Quality Improvement Project to Improve Data Completeness in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Background/Purpose: Minimizing missing data in research registries is a universal challenge. Enrolling patients into a research registry with poor data quality is wasteful and potentially…Abstract Number: 1903 • ACR Convergence 2023
Assessing Disparities Through Missing Race and Ethnicity Data: Results from a Juvenile Arthritis Registry
Background/Purpose: Research databases are missing 25-50% of race and ethnicity, typically related to Black and Hispanic data.1,2The absence of this data can lead to inaccurate…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 18
- Next Page »